BridgeBio Competitors and Similar CompaniesClear all

BridgeBio's competitors and similar companies include Ajinomoto Bio-Pharma Services, R-Pharm, Gubra and Acceleron Pharma.

	BridgeBio BridgeBio is a company focused on discovering and developing drugs for patients with grievous genetic diseases.	Ajinomoto Bio-Pharma Services Ajinomoto Bio-Pharma Services (formerly known as Ajinomoto Althea) is a contract development and manufacturing organization (CDMO).	R-Pharm R-Pharm is a pharmaceutical company.	Gubra Gubra is a biotech company that provides drug discovery programs and pre-clinical contract research services.	Acceleron Pharma Acceleron Pharma is a clinical-stage biopharmaceutical company.
Founding Date	Founding Date 2014	Founding Date 1998	Founding Date 2001	Founding Date 2008	Founding Date 2003
Type	Type Public	Type Subsidiary	Type Private	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Palo Alto, US HQ	Locations San Diego, US HQ Wetteren, BE Visakhapatnam, IN Osaka, JP	Locations Moskva, RU HQ Baku, AZ Illertissen, DE Lawrence Township, US	Locations Hørsholm, DK HQ	Locations Cambridge, US HQ Zug, CH
Employees	Employees 24863% increase	Employees 68610% decrease	Employees 462	Employees 2672% increase	Employees 636% decrease
Financial
Revenue (est.)	Revenue (est.) $502.1m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) kr2.6b (FY, 2025)	Revenue (est.) $92.5m (FY, 2020)
Cost of goods	Cost of goods $21m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods kr73.6m (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit $481.1m (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit kr2.6b (FY, 2025)	Gross profit N/A
Net income	Net income ($732.9m) (FY, 2025)	Net income N/A	Net income N/A	Net income kr1.7b (FY, 2025)	Net income ($166m) (FY, 2020)
Funding
Total funding raised	Total funding raised $ 474.2m	Total funding raised $ 3.5m	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 141.8m